Oxidized low-density lipoprotein
A study involving patients with T2DM by Zander et al
Compared to GLP-1s alone, this program combines advanced medication with behavior change and is designed to boost weight loss
India GLP-1 Receptor Agonists Obesity Drugs Market Insight The India GLP-1 receptor agonists obesity drugs accounted for the largest revenue share in Asia Pacific in 2024, driven by a growing obesity burden, increasing healthcare awareness, and the rapid expansion of urban healthcare infrastructure
In the STEP 1 and SUSTAIN 8 trials, around 40% of the weight lost was lean tissue
As many of these compounds aren't new discoveries, they were researched decades ago and shelved, sometimes for commercial reasons, sometimes simply because society wasn't ready for at-home injecting